Publish time: 2023-02-17 00:00:00
10A-1111123
US Provisional Application
Dengue virus (DENV) cause severe febrile illnesses in humans, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The number of annual dengue fever (DF) cases worldwide is estimated to be 390 million, with 500,000 cases of DHF. Sixty-five percent of the world's population lives in areas with a risk of infection. One major obstacle to producing a vaccine for DENV is that the different serotypes are cross-reactive, and ADE can potentially reduce vaccine efficiency and increase the risk to induce severe illnesses. Previously, we had characterized the ADE-enhancing epitopes of the mAbs localize residue on E protein. Here, we have established mRNA-LNP technique to express antigenic E protein with modification. The serum from modified-E protein mRNA-LNP immunized mice exhibited neutralizing activity against DENV-2 and lowered ADE effect compared to that of wild type E mRNA-LNP immunization. The results of this study can be useful in developing a safe dengue vaccine for prevention of DENV.
- Using an mRNA-LNP immunization strategy, eliciting levels of neutralizing antibody titers higher than previous DNA-based vaccines.
- The serum from modified-E mRNA-LNP immunized mice exhibited higher neutralizing activity against DENV-2 than previously published.
- The serum from modified-E mRNA-LNP immunized mice exhibited lower ADE effect than wild type E mRNA-LNP immunization.
Safety and effectivity of mRNA Vaccine against Dengue Virus Serotype 2.
Han-Chung Wu, Shih-Chieh Su, Hsiu-Ting Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Safety and Immunogenicity of mRNA Vaccine against Dengue Virus Serotype 2 with Modification of Potential Key Residues for Antibody-Dependent Enhancement